Helicobacter pylori drug resistance

therapy changes and challenges

Samantha Flores-Treviño, Soraya Mendoza-Olazarán, Paola Bocanegra-Ibarias, Héctor Jesús Maldonado-Garza, Elvira Garza-González

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

INTRODUCTION: Helicobacter pylori is a Gram-negative bacterium that causes chronic gastritis, dyspepsia, peptic ulcers, and gastric cancer. Over half the world's population is infected with H. pylori, with higher prevalence in developing countries. Areas covered: In this review, current guidelines on H. pylori therapy, such as the Toronto consensus statement, the Maastricht V/Florence consensus report, and the American College of Gastroenterology guidelines, are compared. Also, we analyzed reports of antimicrobial resistance of H. pylori published in PubMed in the last years to determine current antimicrobial resistance worldwide. Expert commentary: Although H. pylori antimicrobial resistance varies by geographic area, its prevalence has been increasing over time, causing therapy failures and low eradication rates. To best optimize the management of H. pylori infection, H. pylori therapy should be based on patterns of local and individual antimicrobial resistance, if possible.

Original languageEnglish
Pages (from-to)819-827
Number of pages9
JournalExpert Review of Gastroenterology and Hepatology
Volume12
Issue number8
DOIs
Publication statusPublished - Aug 2018
Externally publishedYes

Fingerprint

Drug Resistance
Helicobacter pylori
Drug Therapy
Guidelines
Dyspepsia
Helicobacter Infections
Gastritis
Gram-Negative Bacteria
Peptic Ulcer
PubMed
Developing Countries
Stomach Neoplasms
Therapeutics
Population

Cite this

Flores-Treviño, Samantha ; Mendoza-Olazarán, Soraya ; Bocanegra-Ibarias, Paola ; Maldonado-Garza, Héctor Jesús ; Garza-González, Elvira. / Helicobacter pylori drug resistance : therapy changes and challenges. In: Expert Review of Gastroenterology and Hepatology. 2018 ; Vol. 12, No. 8. pp. 819-827.
@article{cfaa28e14c7a480dbbb690ccd8c58abd,
title = "Helicobacter pylori drug resistance: therapy changes and challenges",
abstract = "INTRODUCTION: Helicobacter pylori is a Gram-negative bacterium that causes chronic gastritis, dyspepsia, peptic ulcers, and gastric cancer. Over half the world's population is infected with H. pylori, with higher prevalence in developing countries. Areas covered: In this review, current guidelines on H. pylori therapy, such as the Toronto consensus statement, the Maastricht V/Florence consensus report, and the American College of Gastroenterology guidelines, are compared. Also, we analyzed reports of antimicrobial resistance of H. pylori published in PubMed in the last years to determine current antimicrobial resistance worldwide. Expert commentary: Although H. pylori antimicrobial resistance varies by geographic area, its prevalence has been increasing over time, causing therapy failures and low eradication rates. To best optimize the management of H. pylori infection, H. pylori therapy should be based on patterns of local and individual antimicrobial resistance, if possible.",
author = "Samantha Flores-Trevi{\~n}o and Soraya Mendoza-Olazar{\'a}n and Paola Bocanegra-Ibarias and Maldonado-Garza, {H{\'e}ctor Jes{\'u}s} and Elvira Garza-Gonz{\'a}lez",
year = "2018",
month = "8",
doi = "10.1080/17474124.2018.1496017",
language = "English",
volume = "12",
pages = "819--827",
journal = "Expert Review of Gastroenterology and Hepatology",
issn = "1747-4124",
publisher = "Expert Reviews Ltd.",
number = "8",

}

Flores-Treviño, S, Mendoza-Olazarán, S, Bocanegra-Ibarias, P, Maldonado-Garza, HJ & Garza-González, E 2018, 'Helicobacter pylori drug resistance: therapy changes and challenges', Expert Review of Gastroenterology and Hepatology, vol. 12, no. 8, pp. 819-827. https://doi.org/10.1080/17474124.2018.1496017

Helicobacter pylori drug resistance : therapy changes and challenges. / Flores-Treviño, Samantha; Mendoza-Olazarán, Soraya; Bocanegra-Ibarias, Paola; Maldonado-Garza, Héctor Jesús; Garza-González, Elvira.

In: Expert Review of Gastroenterology and Hepatology, Vol. 12, No. 8, 08.2018, p. 819-827.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Helicobacter pylori drug resistance

T2 - therapy changes and challenges

AU - Flores-Treviño, Samantha

AU - Mendoza-Olazarán, Soraya

AU - Bocanegra-Ibarias, Paola

AU - Maldonado-Garza, Héctor Jesús

AU - Garza-González, Elvira

PY - 2018/8

Y1 - 2018/8

N2 - INTRODUCTION: Helicobacter pylori is a Gram-negative bacterium that causes chronic gastritis, dyspepsia, peptic ulcers, and gastric cancer. Over half the world's population is infected with H. pylori, with higher prevalence in developing countries. Areas covered: In this review, current guidelines on H. pylori therapy, such as the Toronto consensus statement, the Maastricht V/Florence consensus report, and the American College of Gastroenterology guidelines, are compared. Also, we analyzed reports of antimicrobial resistance of H. pylori published in PubMed in the last years to determine current antimicrobial resistance worldwide. Expert commentary: Although H. pylori antimicrobial resistance varies by geographic area, its prevalence has been increasing over time, causing therapy failures and low eradication rates. To best optimize the management of H. pylori infection, H. pylori therapy should be based on patterns of local and individual antimicrobial resistance, if possible.

AB - INTRODUCTION: Helicobacter pylori is a Gram-negative bacterium that causes chronic gastritis, dyspepsia, peptic ulcers, and gastric cancer. Over half the world's population is infected with H. pylori, with higher prevalence in developing countries. Areas covered: In this review, current guidelines on H. pylori therapy, such as the Toronto consensus statement, the Maastricht V/Florence consensus report, and the American College of Gastroenterology guidelines, are compared. Also, we analyzed reports of antimicrobial resistance of H. pylori published in PubMed in the last years to determine current antimicrobial resistance worldwide. Expert commentary: Although H. pylori antimicrobial resistance varies by geographic area, its prevalence has been increasing over time, causing therapy failures and low eradication rates. To best optimize the management of H. pylori infection, H. pylori therapy should be based on patterns of local and individual antimicrobial resistance, if possible.

U2 - 10.1080/17474124.2018.1496017

DO - 10.1080/17474124.2018.1496017

M3 - Review article

VL - 12

SP - 819

EP - 827

JO - Expert Review of Gastroenterology and Hepatology

JF - Expert Review of Gastroenterology and Hepatology

SN - 1747-4124

IS - 8

ER -